AFFYMAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0007 USD | 0.00% |
|
0.00% | +16.67% |
Presenter SpeechUnknown Analyst (Analysts)Good afternoon, and welcome to the 31st Annual JPMor...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Affymax, Inc. is a biopharmaceutical company. The Companyâs product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Companyâs product, OMONTYS.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 26.24K | |
| +22.81% | 47.9B | |
| +46.56% | 41.42B | |
| -1.88% | 40.7B | |
| -6.20% | 28.92B | |
| +11.33% | 25.55B | |
| -21.00% | 19.27B | |
| -1.43% | 12.15B | |
| +30.73% | 12.14B | |
| -0.48% | 11.99B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Transcript : Affymax, Inc. Presents at 31st Annual JPMorgan Healthcare Conference, Jan-10-2013 01